Valuation : Ocular Therapeutix, Inc.

Market Cap 2.52B 2.17B 2.04B 1.86B 3.48B 241B 3.51B 24.34B 9.37B 122B 9.46B 9.25B 388B P/E 2026 *
-7.69x
P/E 2027 * -8.23x
Enterprise Value 2.14B 1.84B 1.74B 1.58B 2.96B 205B 2.99B 20.69B 7.96B 104B 8.04B 7.86B 330B EV / Sales 2026 *
40.5x
EV / Sales 2027 * 23.9x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ocular Therapeutix, Inc.

1 day-4.97%
1 week+2.77%
Current month+4.24%
1 month+18.34%
3 months+25.11%
6 months+10.79%
Current year-9.93%
1 week 10.4
Extreme 10.4
11.48
1 month 9.16
Extreme 9.16
11.74
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 14/04/2024
Director of Finance/CFO 50 19/01/2026
Chief Tech/Sci/R&D Officer 49 19/05/2024
Director TitleAgeSince
Chairman 57 30/06/2019
Director/Board Member 78 04/11/2012
Director/Board Member 66 19/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Sell

Chief Operating Officer

-1,099 0.0005%
25/08/26 Don

Chief Executive Officer

-100,184 0.0473%
24/08/26 Sell

Executive/Senior Manager

-3,035 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-5.01%+2.77%-16.21%+181.83% 2.52B
+0.28%-2.85%+49.28%+89.15% 1,002B
-0.16%-4.30%+51.58%+63.81% 644B
+0.56%-3.03%+19.23%+69.30% 443B
-0.63%-3.09%+29.84%+36.08% 343B
+0.43%-14.61%+11.32%+26.98% 262B
+0.93%-3.19%-1.31%+11.96% 245B
-2.37%-13.84%+37.39%+46.21% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-0.70%-4.47%+25.34%+87.51% 181B
Average -0.61%-3.97%+18.80%+55.47% 353.22B
Weighted average by Cap. +0.03%-4.23%+31.92%+56.05%

Financials

2026 *2027 *
Net sales 52.93M 45.52M 42.95M 39.12M 73.14M 5.06B 73.8M 511M 197M 2.57B 199M 194M 8.15B 102M 88.13M 83.15M 75.75M 142M 9.8B 143M 990M 381M 4.97B 385M 376M 15.78B
Net income -334M -287M -271M -247M -462M -31.96B -466M -3.23B -1.24B -16.21B -1.26B -1.23B -51.49B -324M -279M -263M -240M -448M -31.02B -452M -3.13B -1.21B -15.73B -1.22B -1.19B -49.97B
Net Debt -378M -325M -307M -279M -522M -36.14B -527M -3.65B -1.41B -18.33B -1.42B -1.39B -58.22B -66M -56.76M -53.55M -48.79M -91.2M -6.31B -92.03M -638M -245M -3.2B -248M -242M -10.17B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
10/09/26 US$10.94 -4.66% 563,938
09/09/26 US$11.47 +0.88% 2,804,776
08/09/26 US$11.37 +6.86% 2,737,328
04/09/26 US$10.64 0.00% 1,306,871
03/09/26 US$10.64 -2.39% 2,128,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.47USD
Average target price
27.09USD
Spread / Average Target
+136.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!